Preview

Modern Rheumatology Journal

Advanced search

Diagnostic criteria for idiopathic inflammatory myopathies. Problems of their optimization

https://doi.org/10.14412/1996-7012-2014-3-56-65

Abstract

The paper deals with the problems of optimizing the diagnostic criteria for idiopathic inflammatory myopathies (IIM), a group of heterogeneous rare autoimmune diseases characterized by inflammatory lesion in the skeletal muscles. The representatives of this group are traditionally considered to be polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis. The authors detail the history of classification criteria for IIM from those proposed by T.A. Medsger et al. (1970) relying on its clinical picture, laboratory data and instrumental findings, as well as the criteria (including the first introduced exclusion ones) elaborated by A. Bohan and J.B. Peter in 1975, which remain fundamental in both clinical practice and researches. The basis for the clinical and serological criteria proposed by Y. Troyanov et al. (2005) for IIM is the identification of myositis-overlap syndromes. The classificational (subtype identification) and therapeutic value of the criteria based on clinical and serological characteristics was supported by the Hungarian investigators A. Vancsa et al. (2010) who investigated the relationship between the clinical and therapeutic characteristics of IIM and positivity for myositis-specific and myositis-associated antibodies. The criteria developed by M.C. Dalakas (1991, 2003) are based on the specific immunopathological features of a histological pattern, which allow the differentiation of DM, PM, and inclusion-body myositis from other myopathic syndromes. The 2004 European Neuromuscular Center (ENMC) criteria first identify necrotizing autoimmune myopathy and nonspecific myositis as individual subtypes. The serological classification of IIM, which is based on
the assessment of autoantibodies that play an important role in the pathogenesis of the disease, is of indubitable interest. There is an obvious need for the correct and timely diagnosis of both IIM as a whole and its subtypes in particular, which is complicated by the
heterogeneity of the latter. The proposed approaches to diagnosing and classifying IIM have their advantages and disadvantages so that work in this direction is yet to be under way.

About the Authors

O. A. Antelava
I.M. Sechenov First Moscow State Medical University, Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119991
Russian Federation


S. G. Radenska-Lopovok
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115552
Russian Federation


E. L. Nasonov
I.M. Sechenov First Moscow State Medical University, Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119991 V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115552
Russian Federation


References

1. Антелава ОА, Насонов ЕЛ. Идиопатические воспалительные миопатии. В кн.: Ревматология. Национальное Руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 502–16. [Antelava OA, Nasonov EL. Idiopathic inflammatory myopathies. In: Revmatologiya. Natsional'noe Rukovodstvo [Rheumatology. National Guide]. Nasonov EL, Nasonova VA, editors Moscow:

2. GEOTAR-Media; 2008. P. 502–16.]

3. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–82. DOI: http://dx.doi.org/10.1016/S0140-6736(03)14368-1.

4. Dalakas M. Mechanisms of disease: signaling pathways and immunobyology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006;2(4):219–27. DOI: http://dx.doi.org/10.1038/ncprheum0140.

5. Насонов ЕЛ, Штутман ВЗ, Саложин КВ и др. Клинико-иммунологическая гетерогенность идиопатических воспалительных миопатий. Клиническая медицина. 1995;73(2):3–8. [Nasonov EL, Shtutman VZ, Salozhin KV, et al. Kliniko-immunologichesky heterogeneity of idiopathic inflammatory myopathies. Klinicheskaya meditsina. 1995;73(2):3–8. (In Russ.)]

6. Насонов ЕЛ, редактор. Клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2008. 288 c. [Nasonov EL,editor. Klinicheskie rekomendatsii. Revmatologiya [Clinical recommendations. Rheumatology]. Moscow: GEOTAR-Media; 2008. 288 p.]

7. Medsger Т.А., Bjerrum KB, Braga S, et al. The epidemiology of polymyositis. Am J Med. 1970;48:715–23.

8. DOI: http://dx.doi.org/10.1016/S0002-9343(70)80006-7.

9. De Vere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain. 1975;98(4):637–66. DOI: http://dx.doi.org/10.1093/brain/98.4.637.

10. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7. DOI: http://dx.doi.org/10.1056/ NEJM197502132920706.

11. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7. DOI: http://dx.doi.org/10.1056/NEJM197502202920807.

12. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. Engl J Med. 1991;325(21):1487–98. DOI: http://dx.doi.org/10.1056/ NEJM199111213252107.

13. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004 May;14(5):337–45. DOI: http://dx.doi.org/10.1016/j.nmd.2004.02.006.

14. Baer AN. Advances in the therapy of idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2006;18(3):236–41. DOI: http://dx.doi.org/10.1097/01.bor. 0000218942.12236.74.

15. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705–13. DOI: http://dx.doi.org/10.1002/ana.410380504.

16. Tanimoto K, Nakano K, Kano S, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995;22(4):668–74.

17. Targoff IN, Miller FW, Medsger TA, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9(6):527–35. DOI: http://dx.doi.org/10.1097/00002281-199711000-00008.

18. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am. 2002;28(4):823–32. DOI: http://dx.doi.org/10.1016/S0889-857X(02)00021-2.

19. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–36. DOI:

20. http://dx.doi.org/10.1067/mjd.2002.120621.

21. Van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Potymyositis: an over diagnosed entity. Neurology. 2003;61(3):316–21. DOI: http://dx.doi.org/10.1212/WNL.61.3.316.

22. Troyanov Y, Targоff IN, Tnembtey JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantr bodfes: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84(4):231–49. DOI: http://dx.doi.org/10.1097/01.md. 0000173991.74008.b0.

23. Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011;37(1):100–9. DOI: http://dx.doi.org/10.1590/S1806-37132011000100015.

24. Hilton-Jones D, Miller A, Parton M, et al. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, ondon, 13 June 2008. Neuromuscul Disord. 2010;20(2):142–7. DOI: http://dx.doi.org/10.1016/j.nmd.2009.11.003.

25. Антелава ОА, Раденска-Лоповок СГ, Гусева НГ, Насонов ЕЛ. Современные подходы к классификационным критериям идиопатических воспалительных миопатий. Научно-практическая ревматология. 2007;(5):41–6. [Antelava OA, Radenska-Lopovok SG, Guseva NG, Nasonov EL. Modem approach to classification criteria for idiopathic inflammatory myopathies. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2007;(5):41–6. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2007-20.

26. Vancsa A, Gergely L, Ponyi A, et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine. 2010 Mar;77(2):125–30. DOI: 10.1016/j.jbspin.2009.08.008. Epub 2010 Feb 25.

27. Bronner IM, Hoogendijk JE, Wintzen AR, et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol. 2003;250(4):480–5. DOI: http://dx.doi.org/10.1007/s00415-003-1027-y.

28. Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology. 2003;61(3):288–9. DOI: http://dx.doi.org/10.1212/WNL.61.3.288.

29. Miller FW, Rider LG, Plotz PH, et al. Diagnostic criteria for polymyositis and dermatomyositis. Lancet. 2003;362(9397):1762–3. DOI: http://dx.doi.org/10.1016/S0140- 6736(03)14862-3.

30. Nirmalananthan N, Holton JL, Hanna MG. Is it really myositis? A consideration of the differential diagnosis. Curr Opin Rheum. 2004;16(6):684–91. DOI: http://dx.doi.org/10.1097/01.bor. 0000143441.27065.bc.

31. Hengstrnan GJ, van Engelen BG. Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetition. BMJ. 2004;329(7480):1464–7. DOI: http://dx.doi.org/10.1136/bmj.329.7480.1464.

32. Miiller FW, Rider LG, Plotz PH, et al. Polymyositis: an over diagnosed entity. Neurology. 2004;63(2):402. DOI: http://dx.doi.org/10.1212/WNL.63.2.402.

33. Baer AN. Differential diagnosis of idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2006 Jun;8(3):178–87. DOI: http://dx.doi.org/10.1007/s11926-996- 0023-5.

34. De Bleecker J, Vervaet V, van den Bergh P. Necrotizing myopathy with microvascular deposition of the complement membrane attack complex. Clin Neuropathol. 2004;23(2):76–9.

35. Iaccarino L, Gatto M, Bettio S, et al. Overlap connective tissue disease syndromes. Autoimmun Rev. 2013;12(3):363–73. DOI: 10.1016/j.autrev.2012.06.004. Epub 2012 Jun 26.

36. Ghirardello A, Bassi N, Palma L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2013;15(6):335. DOI: 10.1007/s11926-013-0335-1.

37. Phillips BA, Cala LA, Thickbroom GW, et al. Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle Nerve. 2001;24(11):1526–34. DOI: http://dx.doi.org/10.1002/mus.1178.

38. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112 (Pt 3):727–47. DOI: http://dx.doi.org/10.1093/brain/112.3.727.

39. Badrising UA, Maat-Schieman ML, van Houwelingen JC, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol. 2005;252(12):1448–54. DOI: http://dx.doi.org/10.1007/s00415-005-0884-y.

40. Lindberg C, Persson LI, Bjö rkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand. 1994;89(2):123–31. DOI: http://dx.doi.org/10.1111/j.1600-0404.1994.tb01647.x.

41. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol. 1992;19(9):1385–9.

42. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1996;40(4):581–6. DOI: http://dx.doi.org/10.1002/ana.410400407.

43. Barohn RJ, Amato AA. Inclusion body myositis. Curr Treat Options Neurol. 2000;2(1):7–12. DOI: http://dx.doi.org/10.1007/s11940-000-0019-9.

44. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis) Presentation of six new cases and review of the literature. J Am Acad Dermatol. 1991; 24(6 Pt 1):959–66. DOI: http://dx.doi.org/10.1016/0190-9622(91)70153-S.

45. Arthritis and Allied Conditions: a textbook of rheumatology. 9th ed. Philadelphia, PA: Lea & Febiger; 1979.

46. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–36. DOI:

47. http://dx.doi.org/10.1067/mjd.2002.120621.

48. Sontheimer RD. Dermatomyositis. An overview of recent progress with emphasis on dermatological aspects. Dermatol Clin. 2002;20(3):387–408. DOI: http://dx.doi.org/10.1016/S0733-8635(02)00021-9.

49. Lazarou IN, Guerne PA.Classification, diagnosis and management of idiopathic inflammatory myopathies. J Rheumatol. 2013;40(5):550–64. DOI: 10.3899/jrheum.120682. Epub 2013 Mar 15.

50. Danielsson O, Lindvall B, Gati I, Ernerudh J. Classification and diagnostic investigation in nflammatory myopthies: a study of 99 patientes. J Rheumatol. 2013;40(7):1173–82. DOI: 10.3899/jrheum.120804. Epub 2013 May 1.

51. Linklater H, Pipitone N, Rose MR, et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol. 2013;31(5):767–9.


Review

For citations:


Antelava OA, Radenska-Lopovok SG, Nasonov EL. Diagnostic criteria for idiopathic inflammatory myopathies. Problems of their optimization. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2014;8(3):56-65. (In Russ.) https://doi.org/10.14412/1996-7012-2014-3-56-65

Views: 2389


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)